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A B S T R A C T
Incretin analogues and inhibitors of the breakdown of endogenous incretins are antidiabetic drugs that
increase β-cell proliferation and glucose-stimulated insulin secretion in rodents and humans. Objec-
tives were to test whether exenatide, exenatide extended-release, and sitagliptin can be safely used in
cats, to identify the most effective drug, and to test the effects of prolonged exenatide extended-release
administration. Three cats eachwere given exenatide (0.2–2 μg/kg, q12h, subcutaneously, 5 days), exenatide
extended-release (40–400 μg/kg, subcutaneously, once), and sitagliptin (1–10mg/kg, q24h, orally, 5 days).
Before and after treatment, glucose, insulin and glucagon areas under the curve (AUC) were assessed by
meal response tests (MRT). Exenatide increased insulin AUC by 224%, 258%, 331% and 93%, exenatide
extended-release by 127%, 169%, 178% and 95%, and sitagliptin by 32%, 69%, 62%, and 43%, respectively.
The tested drugs are safe to use in cats and enhance insulin secretion. Incretin-based therapy may be
beneﬁcial in cats with diabetes mellitus.
© 2014 Elsevier Ltd. All rights reserved.
1. Introduction
Incretins are gastrointestinal hormones released during food
intake that increase insulin secretion from β-cells of the pancreas.
The two well-described incretins, glucagon-like peptide 1 (GLP-1)
and glucose-dependent insulinotropic polypeptide (GIP) share most
of their beneﬁcial effects on β-cells such as stimulation of insulin
biosynthesis, stimulation of β-cell proliferation, enhanced β-cell sur-
vival and suppression of β-cell apoptosis (Farilla et al., 2003; Li et al.,
2003). GLP-1 additionally has a suppressive effect on glucagon se-
cretion from pancreatic α-cells as well as various extrapancreatic
effects including the slowing of gastric emptying and of gastroin-
testinal motility, induction of satiation, weight loss, and possibly
also cardiovascular protection (Drucker and Nauck, 2006; Irwin,
2009; Treiman et al., 2010). Biologically active GLP-1 and GIP have
short half-lives (2 and 7 minutes, respectively) and are rapidly de-
graded by the enzyme dipeptidylpeptidase-4 (DPP-4) (Baggio and
Drucker, 2004; Deacon et al., 2000).
Recently, novel classes of anti-diabetic drugs have been devel-
oped that take advantage of the glucoregulatory actions of incretins.
The incretin-based therapeutics comprise direct GLP-1 receptor ago-
nists, such as exenatide and liraglutide, that are also known as
incretin mimetics, and DPP-4-inhibitors, such as sitagliptin, that
reduce the degradation of endogenous GLP-1, the so called incretin
enhancers. Different formulations of the GLP-1 receptor agonist
exenatide exist, requiring either a twice daily (short-acting formu-
lation, e.g. exenatide) or once weekly application (long-acting
formulation, e.g. exenatide extended-release). Both drug classes of
incretin mimetics and enhancers have been shown to increase β-cell
proliferation and glucose-stimulated insulin secretion in rodents and
humans, and are successfully used in the treatment of human type
2 diabetes (Amori et al., 2007; Blevins et al., 2011; Drucker, 2009;
Madsbad et al., 2011; Nauck, 2011).
Because it is assumed that the pathogenesis of diabetes in most
cats is similar to human type 2 diabetes, it can be hypothesized that
incretin-based agents could also represent an interesting thera-
peutic option in cats (Reusch and Padrutt, 2013). There is only limited
data available on the incretin system and the use of incretins in cats.
The existence of a physiological incretin effect has been demon-
strated recently by showing that a larger amount of glucose was
tolerated without development of hyperglycaemia when given orally
and therefore passing through the gastrointestinal tract as com-
pared with direct intravenous infusion of glucose. However, the
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* Corresponding author. Clinic for Small Animal Internal Medicine, Vetsuisse
Faculty, University of Zurich, Winterthurerstr 260, 8057 Zurich, Switzerland. Tel.:
+41 44 6358746; fax: +41 44 6358930.
E-mail address: ezini@vetclinics.uzh.ch (E. Zini).
http://dx.doi.org/10.1016/j.rvsc.2014.12.001
0034-5288/© 2014 Elsevier Ltd. All rights reserved.
Research in Veterinary Science ■■ (2015) ■■–■■
ARTICLE IN PRESS
Please cite this article in press as: I. Padrutt, T.A. Lutz, C.E. Reusch, E. Zini, Effects of the glucagon-like peptide-1 (GLP-1) analogues exenatide, exenatide extended-release, and of
the dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin on glucose metabolism in healthy cats, Research in Veterinary Science (2015), doi: 10.1016/j.rvsc.2014.12.001
Contents lists available at ScienceDirect
Research in Veterinary Science
journal homepage: www.elsevier.com/ locate / rvsc
glucose-dependent insulinotropic effect appeared to be much lower
than that reported in other species (Gilor et al., 2011a, 2011b).
Further investigation of the incretin system in cats showed a rapid
increase of insulin and GLP-1 concentrations after the administra-
tion of oral glucose (Hoenig et al., 2010). To the authors’ knowledge,
only the uses of the GLP-1 receptor agonist exenatide and of the
DPP-4 inhibitor NVP-DPP728 have been evaluated in cats prior to
this study. It had been shown that exenatide, given once at 1 μg/
kg, has a glucose-dependent stimulatory effect on insulin secretion
and a pronounced effect on insulin secretion during normoglycaemia
in cats (Gilor et al., 2011a). The DPP-4 inhibitor NVP-DPP728 showed
signiﬁcant effects to lower plasma glucagon and to enhance insulin
secretion (Furrer et al., 2010).
To assess and compare the safety and eﬃcacy of the two short-
or long-acting GLP-1 receptor agonists exenatide (Byetta, Amylin
Pharmaceuticals Inc., San Diego, CA) and exenatide extended-
release (Bydureon, Amylin Pharmaceuticals Inc.) and of the DPP-4
inhibitor sitagliptin (Januvia, Merck Sharp & Dohme Corp.,
Whitehouse Station, NJ), and to identify their most effective doses,
a dose-escalation study was conducted in healthy cats. In addi-
tion, the effect of a prolonged administration of exenatide extended-
release was investigated.
2. Materials and methods
2.1. Animals
Two groups of healthy domestic shorthair cats were used. The
ﬁrst group, consisting of nine male cats with a median age of 30
months (range: 24–30) and a median body weight of 5.6 kg (range:
4.8–5.8) was used for the dose-escalation study with exenatide,
exenatide extended-release and sitagliptin. The second group, con-
sisting of six male cats with a median age of 13 months (range: 13–
15) and a median body weight of 5.1 kg (range: 4.9–5.6) was used
to test the prolonged administration of exenatide extended-
release. The cats were group-housed, had free access to water and
were fed twice daily at 08:00 am and 06:00 pm with a commer-
cial dry food diet (Adult Indoor, Hill’s Pet Nutrition Inc., Topeka, KS).
Environmental enrichment and social contact were provided on a
daily basis. The experiment was approved by the Veterinary Oﬃce
of the Canton Zurich, Switzerland (nr 122/2011).
Well-being and safety of treatments were assessed in all cats
twice daily throughout the experiment and for an additional week
thereafter by physical examination andmeasurement of bodyweight,
bymonitoring appetite, food andwater intake, and by recording pos-
sible clinical side effects.With regard to the latter, particular attention
was paid to those of the gastrointestinal tract, including vomiting,
soft stools and diarrhoea, because similar side effects are fre-
quently reported in humans (Campbell, 2011; Holst et al., 2010).
Quality of stools was determined according to the Purina Fecal
Scoring System (http://www.purinaveterinarydiets.com). Because
DPP-4 inhibitors may predispose to cystitis and nasopharyngitis in
humans (Amori et al., 2007) clinical signs of the urinary tract, such
as stranguria and pollakisuria, and of the upper respiratory tract,
such as sneezing and nasal discharge, were also noted in individ-
ual medical records for each cat.
2.2. Blood sampling
One week before starting the experiment, a 5 mL blood sample
was obtained from the jugular vein in awake animals. Blood samples
were collected to perform haematological and serum biochemical
proﬁles and to verify the health status of the cats. During the ex-
periment, blood samples were taken via a jugular catheter to
minimize stress reactions of the cats. Jugular catheters were placed
by Seldinger technique under general anaesthesia on each day of
meal response testing (Seldinger, 1953). The animals were fasted
overnight (from 06:00 pm on the evening prior to MRT) to ensure
a minimal risk of aspiration of gastric contents during anaesthesia
for jugular catheter placement, according to AAHA Anesthesia Guide-
lines for Dogs and Cats (Bednarski et al., 2011). To insert the catheter,
sedationwas obtainedwith intramuscular butorphanol (Morphasol®-
4, Dr. E. Graeub AG, Bern, Switzerland) at 2 mg/kg and the α2-
adrenoceptor agonist medetomidine (Domitor®, ProVet AG, Lyssach,
Switzerland) at 5 μg/kg, and general anaesthesia was maintained
with intravenous propofol (Propofol 1% MTC Fresenius, Fresenius
Kabi AG, Bad Homburg, Germany) at 6–8 mg/kg. After implanta-
tion of the jugular catheters, atipamezol, a potent, selective and
speciﬁc antagonist of both centrally and peripherally located α2-
adrenoceptors was administered at 5 μg/kg (Antisedan®, ProVet AG)
to reverse the effects of medetomidine and the cats regained full
consciousness within 5–10 minutes.
Blood samples were collected during each meal response test
(MRT) and were used to measure plasma concentrations of insulin
and glucagon. After collection, samples were immediately trans-
ported to the laboratory on ice, cold-centrifuged and the EDTA
plasma was stored at −80 °C until later analysis. Insulin was mea-
suredwith theMercodia ELISA # 10–1233-01 (Mercodia AB, Uppsala,
Sweden) and glucagon with the rat-glucagon ELISA kit Wako # 297–
57101 (Wako Chemicals GmbH, Neuss, Germany), previously
validated for use in cats by our laboratory. Capillary blood glucose
was measured with the portable glucose meter AlphaTRAK (Abbott
Laboratories, Abbott Park, IL) speciﬁcally designed for dogs and cats,
using samples collected from the inner pinna of the ear. The device
has been shown to accurately measure blood glucose in cats (Zini
et al., 2009).
2.3. Meal response test
The MRT was performed prior to initiation of treatment and on
day 5 of each incretin treatment period. The MRT served to assess
α- and β-cell function in cats (Furrer et al., 2010). One hour after
regaining full consciousness following the placement of the jugular
catheters, 2 mL basal blood samples were taken and the cats were
offered a test meal (Adult Indoor, Hill’s Pet Nutrition Inc.) compris-
ing 50% of their average daily energy requirement (25 g,
approximately 130 kcal). The test meals were rapidly ingested (in
1–2 minutes). Subsequently, 2 mL blood samples were taken from
the jugular catheters at 15, 30, 60, 120 and 300 minutes after food
intake.
2.4. Dose-escalation protocol
Because no data were available regarding exenatide, exenatide
extended-release and sitagliptin administration in cats, a dose-
escalation experiment was conducted for each drug to identify the
occurrence of possible clinical adverse reactions and to assess their
effect on insulin and glucagon secretion. After performing a basal
MRT prior to treatment, which was followed by a 2-week inter-
mission without any medication, treatment was started in all three
drug groups. Exenatide was given subcutaneously to each of three
cats at 0.2, 0.5, 1 and 2 μg/kg for 5 consecutive days, twice daily (at
8:00 am and 8:00 pm). Exenatide extended-release was given sub-
cutaneously to each of three cats at 40, 100, 200 and 400 μg/kg with
single injections (at 8:00 am on day 1). Sitagliptin was given orally
to each of three cats at 1, 3, 5 and 10 mg/kg for 5 consecutive days,
once daily (at 8:00 am). To prevent accumulation of the drugs, every
new dose was anticipated by a 2-week washout period. On day 5
of each treatment dose of exenatide or sitagliptin, or on day 5 fol-
lowing each injection of exenatide extended-release, MRT were
performed starting at 11:00 am in all cats. To assess the effects of
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the drugs, AUC for glucose, insulin and glucagon were compared
with values before drug administration.
2.5. Prolonged administration of exenatide extended-release
Evidence from human medicine showed that a steady state
plasma level of exenatide extended-release may only be reached
after 6–8weeks of treatment (Iwamoto et al., 2009; Kim et al., 2007).
Therefore prolonged administration of exenatide extended-release
was also performed in the present study in cats. Using the two safest
and most effective drug doses estimated from the dose-escalation
experiment, exenatide extended-release was injected subcutane-
ously to three cats at the dose of 100 μg/kg and to another three
cats at the dose of 200 μg/kg, every 7 days, for 5 consecutive weeks.
The MRT was performed 5 days after the last exenatide extended-
release administration and AUC for glucose, insulin and glucagon
were calculated. Values prior to treatment were compared with the
values obtained on day 5 (11:00 am) after the last administration
of exenatide extended-release.
3. Results
3.1. Drug safety and side effects
In six of the nine cats used for the dose-escalation study, mild
and self-limiting diarrhoea and vomiting were observed (Table 1).
Diarrhoea (scores 5 and 6 of the Purina Fecal Scoring System (score
1–7)) was documented in six cats (2 with exenatide, 2 with exenatide
extended-release and 2 with sitagliptin), for a median duration of
4 days (range: 1–5); vomiting was documented in two cats with di-
arrhoea (1 with exenatide, 1 with exenatide extended-release), for
1 and 6 days, respectively. In two cats the side effects developed
during the ﬁrst day of treatment, and in one cat after the second
day of treatment. In three cats side effects ﬁrst occurred with a new
dose, on the ﬁrst day or on the second to ﬁfth day of treatment. In
addition, in four of the six cats side effects were also observed
during the 2-week washout period. Of note, in two cats side effects
were documented once during the experiment and in four cats they
occurred several times (median: 5 times, range: 5–7). The gastro-
intestinal adverse reactions were self-limiting; none of the cats
needed therapeutic intervention and application of the drugs did
not have to be discontinued in any of them. Other side effects were
not documented. General well-being as well as food andwater intake
was not impaired at any time. In the second group of six cats used
for the prolonged administration of exenatide extended-release, side
effects did not occur. Reactions at the injection-site were not ob-
served in any of the cats receiving either exenatide or exenatide
extended-release.
3.2. Dose-escalation protocol
Average glucose AUC after the administration of exenatide,
exenatide extended-release and sitagliptin were similar to corre-
sponding glucose AUC obtained prior to treatment, irrespective of
the dose (Table 2a–c). Hypoglycaemia did not occur with any drug.
All three drugs tested during the dose-escalation protocol en-
hanced meal-dependent insulin secretion, based on MRT. The four
incremental doses of exenatide increased average insulin AUC by
224%, 258%, 331% and 93%, respectively, compared with insulin AUC
in treatment naïve cats (Table 3a). Exenatide extended-release doses
increased average insulin AUC by 127%, 169%, 178%, 95%, respec-
tively, and sitagliptin increased average insulin AUC by 32%, 69%,
62%, 43%, respectively (Table 3b, c).
Exenatide increased and decreased glucagon AUC, whereas
exenatide extended-release and sitagliptin decreased glucagon AUC,
based onMRT. The three lower doses of exenatide yielded an average
Table 1
Overview of gastrointestinal side effects due to exenatide, exenatide extended-release and sitagliptin. D = diarrhoea, V = vomitus.
Cats with
clinical signs
D V Onset of clinical
signs per cat
Total frequency of
clinical signs per cat
Cats with clinical signs
during washout
Exenatide 2 2 1 Dose 1, day 1
Dose 3, day 1
6 times
Once
1
Exenatide extended-release 2 2 1 Dose 1, day 2
Dose 2, day 1
5 times
7 times
2
Sitagliptin 2 2 – Dose 1, day 1
Dose 4, day 3
5 times
Once
1
Table 2
Glucose AUC concentrations with exenatide (a), exenatide extended-release (b) and sitagliptin (c) at incremental doses. The areas are expressed in (mmol/L) × minutes.
(a)
Exenatide dose Prior to treatment 0.2 μg/kg q12h 0.5 μg/kg q12h 1 μg/kg q12h 2 μg/kg q12h
Cat A 1459 1595 1522 1601 1324
Cat B 1454 1594 1597 1960 1854
Cat C 1656 1519 1423 1516 1271
(b)
Exenatide extended-release dose Prior to treatment 40 μg/kg 100 μg/kg 200 μg/kg 400 μg/kg
Cat D 1459 1964 2033 6164 1878
Cat E 1459 1970 1634 1726 1653
Cat F 1913 1709 1498 1545 1634
(c)
Sitagliptin dose Prior to treatment 1 mg/kg q24h 3 mg/kg q24h 5 mg/kg q24h 10 mg/kg q24h
Cat G 1573 1763 1539 1379 1660
Cat H 1452 1508 1311 1379 1315
Cat I 1222 1276 1381 1364 1491
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increase of 14%, 35%, 46%, respectively, while the highest dose of
exenatide decreased glucagon AUC by 14% compared with gluca-
gon AUC obtained in treatment-naïve cats (Table 4a). Exenatide
extended-release decreased average glucagon AUC by 15%, 8%, 1%
and 16%, respectively, and sitagliptin decreased average glucagon
AUC by 34%, 29%, 16% and 22%, respectively (Table 4b, c).
3.3. Prolonged administration of exenatide long-acting
Average glucose AUC after the prolonged administration of
exenatide extended-release was similar to glucose AUC obtained
prior to treatment, with either dose (Table 5a). Hypoglycaemia was
not documented.
Based on MRT, the prolonged administration of exenatide
extended-release 100 μg/kg/week for 5 weeks decreased average
insulin AUC by 8% compared with treatment-naïve cats (Table 5b);
of note, although insulin AUC was reduced, the insulin AUC from
0 to 120 minutes in treated cats was 40% higher than in untreated
cats. Exenatide extended-release at the dose of 200 μg/kg/week for
5 weeks increased average insulin AUC duringMRT by 15% (Table 5b)
and the insulin AUC from 0 to 120 minutes in treated cats was 116%
higher than in untreated cats.
Based on MRT, the prolonged administration of exenatide
extended-release 100 μg/kg/week for 5 weeks increased average glu-
cagon AUC by 253% in comparison with treatment-naïve cats.
Exenatide extended-release at the dose of 200 μg/kg/week for 5
weeks increased average glucagon AUC by 3% (Table 5c).
4. Discussion
The results of the dose-escalation protocol showed that exenatide,
exenatide extended-release and sitagliptin were all able to enhance
insulin secretion in healthy cats. The GLP-1 agonists exenatide and
exenatide extended-release showed more pronounced effects than
the DPP-4 inhibitor sitagliptin which is consistent with ﬁndings in
humans, where GLP-1 agonists are superior in achieving good
glycaemic control (Karagiannis et al., 2012; Nauck, 2011). GLP-1 leads
to an increase of insulin secretion in humans due to direct effects
on pancreatic β-cells, including a stimulation of insulin biosynthe-
sis and of β-cell proliferation, as well as enhanced β-cell survival
and resistance to apoptosis (Farilla et al., 2003; Li et al., 2003).
Because most diabetic cats suffer from a disease that shares many
similarities to human type 2 diabetes (Reusch and Padrutt, 2013),
the enhanced insulin secretion achieved in healthy cats may suggest
that exenatide, exenatide extended-release and sitagliptin could be
beneﬁcial also in diabetic cats, possibly improving β-cell function
or viability via one or more of the mechanisms demonstrated in
humans.
Prolonged administration of exenatide extended-release en-
hanced postprandial insulin secretion more than in untreated cats,
Table 3
Insulin AUC concentrations with exenatide (a), exenatide extended-release (b) and sitagliptin (c) at incremental doses. The areas are expressed in (pmol/L) × minutes.
(a)
Exenatide dose Prior to treatment 0.2 μg/kg q12h 0.5 μg/kg q12h 1 μg/kg q12h 2 μg/kg q12h
Cat A 4183 30,348 23,582 28,408 10,244
Cat B 5529 19,649 29,192 26,921 13,241
Cat C 4401 9281 12,719 23,555 11,853
(b)
Exenatide extended-release dose Prior to treatment 40 μg/kg 100 μg/kg 200 μg/kg 400 μg/kg
Cat D 3305 10,406 24,410 24,768 21,492
Cat E 10,409 16,833 11,460 16,485 12,700
Cat F 8576 23,229 23,983 20,606 9205
(c)
Sitagliptin dose Prior to treatment 1 mg/kg q24h 3 mg/kg q24h 5 mg/kg q24h 10 mg/kg q24h
Cat G 4183 30,348 23,582 28,408 10,244
Cat H 5529 19,649 29,192 26,921 13,241
Cat I 4401 9281 12,719 23,555 11,853
Table 4
Glucagon AUC concentrations with exenatide (a), exenatide extended-release (b) and sitagliptin (c) at incremental doses. The areas are expressed in (ng/L) × minutes.
(a)
Exenatide dose Prior to treatment 0.2 μg/kg q12h 0.5 μg/kg q12h 1 μg/kg q12h 2 μg/kg q12h
Cat A 46,997 36,082 37,799 63,697 30,441
Cat B 75,334 53,183 69,441 105,421 44,998
Cat C 52,298 111,341 129,375 87,462 75,687
(b)
Exenatide extended-release dose Prior to treatment 40 μg/kg 100 μg/kg 200 μg/kg 400 μg/kg
Cat D 47,175 61,473 48,565 55,003 36,373
Cat E 38,924 27,702 39,594 49,246 53,491
Cat F 94,955 64,379 78,101 74,924 61,893
(c)
Sitagliptin dose Prior to treatment 1 mg/kg q24h 3 mg/kg q24h 5 mg/kg q24h 10 mg/kg q24h
Cat G 64,787 38,913 40,615 56,009 42,378
Cat H 59,742 35,010 35,562 41,004 34,756
Cat I 38,372 31,242 39,136 40,671 49,658
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at both 100 and 200 μg/kg/week. The effects on insulin secretion
were more pronounced at the higher dose, where the meal-
induced enhancement of insulin concentration of the AUC from 0
to 120 minutes was 116% higher after the 5-week application of the
drug than in treatment naïve cats. The comparison of AUCs from 0
to 120 minutes of untreated vs. treated cats (40% increase of AUC
for 100 μg/kg and 116% increase for 200 μg/kg) showed a pro-
nounced post prandial enhancement of insulin secretion for both
doses, whereas the total AUC of insulin was less affected by exenatide
extended-release, with amild increase at 200 μg/kg and even a slight
decrease with 100 μg/kg. The reason for the mild effect on insulin
AUC is probably due to the fast insulin drop observed after the post-
prandial insulin peak in treated cats. This drop in insulin secretion
after the time period of 120 minutes could possibly be explained
by counterregulatory mechanisms against hypoglycaemia in healthy
cats. In dogs, counterregulatory elevations of glucagon, cortisol and
lactate have been observed after portal administration of GLP-1
(Ionut et al., 2005), and studies in humans show that in the pres-
ence of exenatide there are strongly preserved counterregulatory
mechanisms during hypoglycaemia (Degn et al., 2004). Although
during the present study hypoglycaemia did not occur, similar
counterregulatory effects might have prevented impending sub-
stantial drops in blood glucose in the healthy cats.
A tachyphylactic effect of the testeddrugs during the dose-escalation
protocol and the prolonged administration of exenatide extended-
release seems rather unlikely. Also after chronic administration of GPL-1
receptor agonists, despite sustained elevations in the circulating levels
of the drug, no evidence for tachyphylaxis or clinically signiﬁcant re-
ceptor desensitization has been observed in human clinical studies
(Hargrove et al., 1995; Nauck et al., 1996). Exendin 4 has been found
to be more potent than native GLP-1 in producing GLP-1 receptor de-
sensitization in vitro, but chronic exposure to exendin 4 in normal or
transgenicmicewas not associatedwith signiﬁcant downregulation of
GLP-1 receptor–dependent responses coupled to glucose homeosta-
sis (Baggio and Drucker, 2004; Baggio et al., 2004).
The strong effects on insulin peak secretion and the absence of any
side effects aswell as the convenient therapy regimen of a onceweekly
injection may make the prolonged administration of exenatide
extended-release amore favourable optionover exenatide and sitagliptin
in diabetic cats.
Besides the effect of GLP-1 on insulin, incretins also decrease glu-
cagon secretion from pancreatic α-cells (Drucker and Nauck, 2006). In
diabetic humans, GLP-1 agonists aswell as DPP-4 inhibitors reduce glu-
cagon secretion. In a previous study in healthy cats, the administration
of the DPP-4 inhibitor (NVP-DPP728) yielded a signiﬁcant reduction of
plasma glucagon concentrations after anMRT (Furrer et al., 2010). Con-
sistent with these ﬁndings, results of the present dose-escalation
protocol showed a decrease of glucagon secretionwith sitagliptin and
exenatide extended-release,while exenatide showed a dose-dependent
increase of glucagon followed by a decrease. The reason for this
result is unclear. It is known that in the case of hypoglycaemia,
counterregulatory secretion of glucagon is preserved even with phar-
macological concentrations of GLP-1 (Drucker and Nauck, 2006).
Although themeasuredglucose valuesduringMRTdidnotdrop, itmight
be that the observed increase of glucagon secretionwaspart of thephys-
iologic compensation against hypoglycaemia in healthy cats.
Furthermore, the decrease of glucagon demonstratedwith the highest
exenatide dose (i.e., 2 μg/kg)may be explained by the fact that the same
dose lead to the lowest increase of insulin concentration, perhaps re-
ducing the counterregulatory effect on glucagon.
Similar to most doses of exenatide, prolonged administration of
exenatide extended-release increased glucagon secretion, in particu-
lar at the lower dose (100μg/kg). The reason for the increased glucagon,
which contrasts the effect of exenatide extended-release given for a short
period during the dose-escalation protocol, is uncertain. At 100 μg/kg
of exenatide extended-release, the cats showed lower insulin secre-
tion, making the above hypothesis of counterregulation provided for
the highest dose of exenatide unlikely. The present ﬁndings of this study
cannot provide evidence of a suppressive effect of exenatide, exenatide
extended-release, and sitagliptin on glucagon concentrations. Further
studies are required to assess the effects of incretin mimetics and en-
hancers on glucagon.
The results of glucose AUC obtained after treatment did not differ
from those achieved prior to treatment with any of the drugs tested,
and no lowering effect on fasting glucose was observed. Since only
healthy animalswere used for this study, counteracting hormones, such
as glucagon but also norepinephrine (Rand et al., 2002), might have
played a substantial role in preventing hypoglycaemia or even slight
drops in blood glucose concentrations. A recent study in healthy rats
showed an unexpected rise of glucose levels after acute administra-
tion of exenatide caused by stimulation of the sympathetic nervous
system (Perez-Tilve et al., 2010). A similar effect might be present also
in healthy cats, possibly explaining the lack of glucose lowering effects
of incretins under our test conditions, in healthy normoglycaemic cats.
Table 5
Glucose (a), insulin (b) and glucagon (c) AUC concentrations with exenatide extended-release at 100 and 200 μg/kg/week for 5 weeks. The areas are expressed in (mmol/L)
× minutes.
(a)
Exenatide extended-
release dose
Prior to
treatment
100 μg/kg q7d
for 5 weeks
Exenatide extended-
release dose
Prior to
treatment
200 μg/kg q7d
for 5 weeks
Cat J 1208 1202 Cat M 1347 1238
Cat K 1188 1200 Cat N 1378 1264
Cat L 1201 1255 Cat O 1254 1206
(b)
Exenatide extended-
release dose
Prior to
treatment
100 μg/kg q7d
for 5 weeks
Exenatide extended-
release dose
Prior to
treatment
200 μg/kg q7d
for 5 weeks
Cat J 11,968 6003 Cat M 18,691 11,443
Cat K 8646 15,065 Cat N 11,831 17,586
Cat L 13,193 9975 Cat O 7591 14,891
(c)
Exenatide extended-
release dose
Prior to
treatment
100 μg/kg q7d
for 5 weeks
Exenatide extended-
release dose
Prior to
treatment
200 μg/kg q7d
for 5 weeks
Cat J 136,516 170,301 Cat M 73,051 144,057
Cat K 45,742 641,230 Cat N 157,142 89,090
Cat L 133,196 301,457 Cat O 70,719 78,143
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As an additional beneﬁt to improved glycaemic control, the GLP-1
agonists exenatide and exenatide extended-release are associated
with weight loss in diabetic patients, whereas DPP-4 inhibitors seem
to be weight neutral (Blevins et al., 2011; Drucker et al., 2008;
Madsbad et al., 2011). Body weight of all the cats was assessed on
aweekly basis and remained stable during the study period. It cannot
be excluded that longer duration of treatmentmight also have caused
weight loss in cats.
The results of this study show that exenatide, exenatide extended-
release and sitagliptin can all cause gastrointestinal side effects in
cats. In particular, cats enrolled in the dose-escalation protocol
showed mild and self-limiting diarrhoea and vomiting that were
independent of the drug and dose given. Exenatide extended release
administered to cats over a period of 5 weeks did not appear to
cause gastrointestinal side effects.
Exenatide is generally well tolerated in humans, although com-
monly reported side effects include mild gastrointestinal symptoms
like nausea, vomiting and diarrhoea, which usually resolve after 4–8
weeks of treatment (Campbell, 2011; Holst et al., 2010). Gastroin-
testinal symptoms are dose-dependent and gradual dose increase
can be used to lessen symptoms (Fineman et al., 2004). In the present
study, clinical signs with exenatide were similar to humans, but their
occurrence did not appear to be dose-dependent, at least within the
dose range tested here, possibly suggesting a species-speciﬁc
difference.
The frequency of gastrointestinal side effects with exenatide
extended-release is lower than with exenatide, but the former com-
monly causes injection-site reactions in humans (Blevins et al., 2011;
Drucker et al., 2008; Madsbad et al., 2011). In cats, side effects with
exenatide extended-release were few in the dose-escalation pro-
tocol and none occurred during the prolonged administration, similar
to humans. Obvious reactions at the injection site were not docu-
mented, suggesting that exenatide extended-release would be safe
if used in diabetic cats. DPP-4 inhibitors, like sitagliptin, are known
to cause less gastrointestinal side effects than GLP-1 agonists, but
are associated with an increased risk of cystitis, nasopharyngitis and
headache (Amori et al., 2007). None of the cats of the study showed
respiratory signs or urinary tract disease.
Limitations of the study that need to be mentioned are the small
number of cats included that prevented inferential statistical anal-
ysis to be performed, as well as the lack of blood samples collected
after treatment to identify possible side effects on haematological
and serum biochemical proﬁles. Because of the intensive study pro-
tocol and multiple blood sampling of considerable blood volumes,
the allowed number of research animals was limited to ﬁfteen cats
by the veterinary oﬃce. To prevent anaemia, on the grounds of
animal welfare considerations as well as to preclude potential neg-
ative effects of anaemia on the test results, the study period was
limited to the described four incremental doses of each drug.
This study showed that exenatide, exenatide extended-release
and sitagliptin were used safely and were able to enhance insulin
secretion in a small number of healthy cats. The use of incretin-
based therapy may represent a novel treatment option for
management of diabetic cats, andwarrants further studies in a larger
population of healthy cats, as well as diabetic cats.
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